The European Commission has recently approved Sutent (sunitinib) as a medicine for treating patients with pancreatic neuroendocrine tumors (NET).
The drug is now indicated to treat unresectable metastatic, well-differentiated pancreatic NET in adults with disease progression.
The approval was based on a Phase III study which was reported in January. The study showed that patients with pancreatic NET and treated with Sutent had progression-free survival of 1.4 months, compared with 5.5 months for placebo.
Please visit healthreason.com for more health related articles.
